Recently, the China Cardiovascular Health and Disease Report 2019 was officially released. As the chronic disease with the highest incidence rate and mortality in China, cardiovascular disease has again aroused people's attention and discussion. According to the report, the prevalence of cardiovascular diseases in China is on the rise. Among them, the number of cardiovascular diseases has reached 330 million. Cardiovascular disease death accounts for more than 40% of the disease death of Chinese residents, which poses a great threat to life and health.

  With the increase of the number of patients, the market scale is expanding. According to the survey data of the Chinese Academy of Commerce and Industry, the market size of cardiovascular health-related drugs in China has increased from 158.8 billion yuan in 2015 to 212.2 billion yuan in 2019, with a compound annual growth rate of 7.5%. It is expected to further increase from 217.5 billion yuan in 2020 to 247.7 billion yuan in 2024 with a compound annual growth rate of 3.3%.

    

In the face of a vast market of hundreds of billions, many enterprises and teams have entered the market. For example, Zhongjia Hengtai, which uses vascular endothelial function test to move the cardiovascular health management gateway forward; Another example is that Dr. Du Enpeng's team uses magnetorheology to lower blood pressure and physical therapy to treat cardiovascular diseases; Low-light medical treatment focuses on cardiovascular imaging diagnosis and treatment equipment, etc.
Create medical-grade smart wearable devices

The changes of vital sign data such as blood pressure, blood oxygen and body temperature have important reference significance for cardiovascular health. Therefore, for cardiovascular health management, intelligent wearable devices are a good choice. They can help people continuously monitor multi-dimensional health data such as heart rate, ECG, sleep and exercise for a long time, so as to assess health risks.

    Although when smart wearable devices were just popular a few years ago, because most products were not up to medical level, smart wearable devices were not accepted by the public. However, with the iteration of technology, intelligent wearable devices are increasingly recognized by people.

   Relevant data show that the public's acceptance of intelligent wearable devices has been relatively high at present. The average wearing time of active users is more than 15 hours, and the average wearing time is longer as they get older. Among them, the average wearing time of people over 60 is more than 17 hours, and the measurement frequency of ECG data becomes more frequent with the growth of age, Some people use intelligent wearable devices to monitor heart health has become a part of daily life.

   For cardiovascular related diseases, early prevention and detection are very important, and most patients do not realize what kind of disease they have or are suffering from at the early stage, so they do not go to treatment in time. However, acute myocardial infarction and other diseases often occur very suddenly. At this time, patients need to go to hospital every second. When we wear this kind of intelligent device, users can easily early warning the adverse changes of the body from the data changes of relevant physical signs through real-time monitoring, and seek medical treatment in time. In case of such events, medical staff can also judge the patient's physical status first and prepare as early as possible.

  In this regard, FRCLINK developed the smart bracelet HB1 and smart watch H1 for monitoring cardiovascular health as early as the epidemic. This type of product can carry out 24-hour heart rate monitoring, sleep monitoring, ECG monitoring, HRV analysis, blood oxygen detection, etc. It also pioneered the application of fingertip measurement technology to watches and bracelets, using fingertip blood pressure and fingertip blood oxygen measurement functions.

 Main four highlights of FRCLINK's products in terms of technical advantages

The first is medical grade. The accuracy of FRCLINK's ECG (electrocardiogram) and PPG (photoelectric plethysmogram) function in judging atrial fibrillation is 94.76% and 93.27% respectively. The cumulative shipment of ECG wear worldwide is 200000. The customer has recently obtained the CFDA certificate. Most smart watch manufacturers can only produce smart watches in the ordinary sense, and cannot develop medical-grade health monitoring smart watches.

    

Second, multi-dimensional. Through fingertip optical sensors, gyroscopes, acceleration sensors, barometers, bioelectricity, GPS and other sensors, MicroHealth's watch can obtain data such as heart rate, blood oxygen, blood pressure, sleep, exercise, HRV, mental pressure, body fat rate, and realize multi-dimensional management of health.

    

The third is the algorithm model. FRCLINK has accumulated the core algorithms of automatic motion recognition, automatic diagnosis of atrial fibrillation, REM sleep, ECG diagnosis, arteriosclerosis index, mental stress and so on through the accumulated data of 10 million users, and is still in the process of iterative upgrading.

    

Fourth, high-quality R&D team. The R&D personnel of FRCLINK basically graduated from Harbin Institute of Technology, University of Electronic Science and Technology, Nanjing University, Central China University of Science and Technology and other famous universities. There are also many R&D personnel from well-known enterprises such as BGI, Lexin and Asian Optics.

    

FRCLINK will bring more creative and high-quality smart wearable products to you in 2024.